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Abstract
Background: The aim of this study is to investigate the inter and intra-rater reliability, repeatability, and reproducibility
of pulmonary transit time (PTT) measurement in patients using contrast enhanced ultrasound (CEUS), as an indirect
measure of preload and left ventricular function.
Methods: Mean transit times (MTT) were measured by drawing a region of interest (ROI) in right and left cardiac
ventricle in the CEUS loops. Acoustic intensity dilution curves were obtained from the ROIs. MTTs were calculated by
applying model-based fitting on the dilution curves. PTT was calculated as the difference of the MTTs. Eight raters
with different levels of experience measured the PTT (time moment 1) and repeated the measurement within a week
(time moment 2). Reliability and agreement were assessed using intra-class correlations (ICC) and Bland-Altman
analysis. Repeatability was tested by estimating the variance of means (ANOVA) of three injections in each patient at
different doses. Reproducibility was tested by the ICC of the two time moments.
Results: Fifteen patients with heart failure were included. The mean PTT was 11.8 ± 3.1 s at time moment 1
and 11.7 ± 2.9 s at time moment 2. The inter-rater reliability for PTT was excellent (ICC = 0.94). The intra-rater reliability
per rater was between 0.81–0.99. Bland-Altman analysis revealed a bias of 0.10 s within the rater groups. Reproducibility
for PTT showed an ICC = 0.94 between the two time moments. ANOVA showed no significant difference between the
means of the three different doses F = 0.048 (P = 0.95). The mean and standard deviation for PTT estimates at three
different doses was 11.6 ± 3.3 s.
Conclusions: PTT estimation using CEUS shows a high inter- and intra-rater reliability, repeatability at three different
doses, and reproducibility by ROI drawing. This makes the minimally invasive PTT measurement using contrast
echocardiography ready for clinical evaluation in patients with heart failure and for preload estimation.
Keywords: Contrast enhanced ultrasound, Echocardiography, Indicator dilution technique, Intra-class correlation, Mean
transit time, Pulmonary transit time, Reliability
Background
Pulmonary blood volume quantification by transpulmonary
dilution analysis is an essential part of the hemodynamic
evaluation to guide fluid management in anesthesia and
intensive care practice. Recently, contrast-enhanced ultra-
sound (CEUS) has been proposed as a minimally-invasive,
alternative method for pulmonary transit time (PTT)
estimation [1–3]. This technique uses transthoracic echo-
cardiography (TTE) to visualize the transcardiac passage of
an ultrasound contrast-agent (UCA) bolus injected in a
peripheral vein. Indicator dilution curves (IDCs) are then
derived from the acoustic backscatter of the UCA bolus in
the four heart chambers. The mean transit time (MTT) of
these acoustic IDCs can be estimated by different methods.
The most frequently used methods in clinical practice are
based on assessment of the “peaks” of the IDCs or “frame
counting” of the appearance of the first bubbles in the
heart chambers [3–5]. We estimate the MTT by model
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fitting using the local density random walk (LDRW) model,
which takes into account the Brownian motion of the bolus
contrast in the blood stream through the pulmonary
vessels and heart chambers [1, 2, 6, 7].
In previous studies, we demonstrated that volume
estimation by CEUS, resulting from the multiplication of
the flow by the PTT (i.e. the difference between the
MTTs of the left atrium and the right ventricle (RV)),
showed excellent agreement with the actual volumes,
both in-vitro and in-vivo [2, 6]. Moreover, it showed
even better accuracy than transpulmonary thermodilu-
tion volume estimation [1, 8]. However, the reliability of
PTTs derived with CEUS and the LDRW in-vivo has not
been established. Therefore, in this study we investigated
the reliability and reproducibility of the assessment of PTT
with CEUS using the LDRW model, in patients referred
for cardiac resynchronization therapy. We also investi-
gated the effect of different UCA doses on the PTT
measurement. In addition, to evaluate the complexity of
the PTT assessment by means of CEUS-recording
analysis, PTT was also estimated by non-physicians. If
also non-physicians can obtain reliable measurements,
this would imply a fast learning curve, favoring the
method adoption in clinical practice. Therefore, our
second objective was to evaluate the reliability and




As per local hospital protocol, all patients referred for
cardiac resynchronization therapy underwent extensive
echocardiographic evaluation including contrast enhanced
ejection fraction measurements. This patient population
scheduled for contrast enhanced TTE to assess ejection
fraction and eligibility were included for this observational
study. In general, these were patients with symptomatic
heart failure, a decreased ejection fraction, and QRS-
widening by more than 120 ms. Patients were excluded in
case of atrial fibrillation, an acute coronary syndrome
within the past three months, a known allergy to sulphur-
hexafluoride, or a poor acoustic window (impossibility to
visualize an apical 4-chamber view). The Institutional
Review Board of the Catharina Hospital Eindhoven
approved the study, and written informed consent for use
of echocardiography data for scientific purposes was
obtained from all subjects.
Measurement protocol
Patients referred for a left ventricle (LV) dyssynchrony
evaluation received a standard of care CEUS echocardi-
ography according to our hospital protocol (Fig. 1). In
all patients, an 18-gauge catheter was inserted in a
peripheral vein of the fore-arm and the patient was
positioned in left lateral position. The UCA was admin-
istered according to our hospital CEUS protocol. All
contrast-enhanced TTE imaging was performed by an
experienced imaging-cardiologist (PH) using an iE33
ultrasound scanner equipped with a S5-1 transducer
(Philips Healthcare, Andover, MA, USA). Four chamber
apical views were obtained using harmonic imaging at
1.3–2.6 MHz, a low mechanical index (MI) of 0.19 to
reduce microbubble destruction, a frame rate of 23 Hz,
and a dynamic range of 50 dB with linear post-
processing.
SonoVue® (Bracco SpA, Milan, Italy) consisting of
microbubbles with a SF6 gas enclosed in a phospholipids
monolayer shell was used as UCA. These microbubbles,
with an average size of 3 to 9 μm, pass the pulmonary
circulation and can be visualized in both RV and LV [9].
After a peripheral bolus injection, the passage of micro-
bubbles through the right and left heart was visualized
from a four chamber apical view without breath-hold by
selecting the proper probe angle, to minimize movement
artifacts. We diluted 1 ml SonoVue® in saline (1:400,
1:200, and 1:100) and injected a bolus of 10 ml of the
solution. Three different CEUS loops were recorded in
consistent consecutive order. The injections were per-
formed in a reproducible way as a manual instantaneous
bolus and each dose was administered as soon as the
recirculating microbubbles disappeared from the left
ventricle. These are doses lower than those used for left
ventricular opacification [10], but give good opacification
of the ventricles while providing an approximately linear
relationship between the UCA concentration and the
measured acoustic intensity; the latter is a prerequisite
for application of the indicator dilution theory [1, 2].
Reliability was tested by eight raters: four physicians
who were all experienced with echocardiography but
with different levels of experience with measuring MTT
(one rater was experienced (IH), one rater had some
experience (HK), and two had experience in endocardial
border tracing (PH, JD)), and four technicians from the
Eindhoven University of Technology of whom three
were inexperienced with echocardiography and MTT
(HA, GW, AG) and one was an expert in the field
(MM). All raters received a detailed guide for drawing
ROIs in both RV and LV at the two time moments. Each
rater received the same fifteen anonymized ultrasound
apical four chamber view loops following the injection
of a SonoVue® in saline bolus at a dilution of 1:200
(Fig. 1). The raters were instructed to draw regions of
interest (ROIs) independently within the endocardial bor-
ders of the RV and LV throughout the cardiac cycle; no
specified ROI surface was predefined (Additional file 1).
ROI position was fixed over all the frames. Movement of
borders or valve structures within the ROI will create arti-
facts in the IDC. Therefore, the instructions emphasized
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that the ROIs should be kept within the endocardial
border during the entire cardiac cycle. To this end, the
freeform splines ROIs were drawn using QLab® 8 software
(Philips, Healthcare, Andover, MA, USA). The acoustic
intensity over time in the ROIs was expressed as an IDC.
To test the reproducibility of the measurement itself, the
raters repeated the drawings in the same dataset within a
week interval; these time points are referred to as time
moment 1 and 2. The raters were blinded for their previ-
ous results and to the measurement outcome; also the
order of the patients in the dataset was changed between
time moment 1 and 2. The extracted data were saved as
Excel files and were afterwards analyzed using a custom
software to fit the local density random walk (LDRW)
model to the measured IDCs; the method was imple-
mented in MATLAB® 2009b (The Mathworks, Natick,
MA, USA) [11]. The interdose repeatability was tested by
one rater (IH) who drew ROIs in all three different echo
loops at the three different doses for the fifteen patients.
Thereby, ROI size was measured and the difference in
MTT in the fifteen cine loops at three different doses.
The IDCs were fitted by the LDRW model by an inde-
pendent researcher (GW). The fitting was performed
automatically as described by Mischi et al. [11]. The ana-
lysis of the acoustic IDC provides parameters related to
the convection and dispersion of the injected SonoVue®
bolus including the MTT [2, 12]. The difference in MTT
(ΔMTT) between LV and RV, presenting the PTT, was
derived by subtraction [7].
Statistical analysis
The analysis and rendering of this observational study
are in line with the guideline for reporting reliability and
agreement studies (GRRAS) [13]. The intra-class correl-
ation for random effects models based on repeated-
measures ANOVA was used to evaluate intra-rater and
inter-rater reliability [14]. These were analyzed for the
different time moments 1 and 2 and the different classes:
physicians versus technicians. The level of agreement
between the PTT measured by physicians and technicians
was determined with Bland-Altman analysis to estimate
the feasibility of CEUS using MedCalc Statistical Software
Fig. 1 The passage of a bolus of SonoVue® through the right atrium and ventricle (panel b) and left atrium and ventricle (panel c). ROIs are
drawn in the right and left ventricle (not shown, see Additional file 1). The acoustic intensities according to panel a, b, and c are expressed in
panel d. The acoustic dilution curves of the right (blue indicator dilution curve (IDC)) and left ventricle (red IDC) are fitted according to the local
density random walk model and the mean transit times (vertical black lines) are then calculated
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version 14.8.1 (MedCalc Software bvba, Ostend, Belgium)
[15]. The distributions of the MTTs of both ventricles and
the PTTs were tested by the Shapiro-Wilk test. The MTTs
and PTTs are presented as mean and standard deviation
(for normal distributions) or median and interquartile
ranges (for non-normal distributions). Coefficients of
variation were measured for the PTT and computed
among the rater groups. The repeatability of the three dif-
ferent doses and different loops was tested using univariate
ANOVA analysis. The ROI size was tested for its distribu-
tion as described above for PTT. Statistical analyses were
performed using IBM SPSS statistics for Windows version
22.0 (IBM©, Armonk, NY, USA).
Results
Fifteen patients (12 men and 3 women) were enrolled in
the study. Mean age was 67 ± 7 years with an ejection
fraction of 31 ± 11 % (Table 1). The transit times at any
time moment had a normal distribution according to
the Shapiro-Wilk test. The mean MTT of the RV was
8.5 ± 3.1 s and 8.7 ± 3.1 s at time moment 1 and 2,
respectively. For the LV, these values were 20.4 ± 5.6 s
and 20.3 ± 5.5 s, respectively. The mean PTT was
11.8 ± 3.1 s at time moment 1 and 11.7 ± 2.9 s at time
moment 2.
The MTT assessments made at the two different time
moments per rater showed a high reliability with intra-
class correlation coefficient (ICC) for the PTT equal to
0.94 (95 % CI, 0.90–0.97). For the MTTs of the RV and
LV, the ICC was 0.98 (95 % CI, 0.97–0.99) and 0.99
(95 % CI, 0.98–0.99), respectively (Table 2 and Fig. 2). In
Fig. 2, the peak of the IDCs of the different ROIs, drawn
by the raters, is visualized and its effect on the MTT of
the LV evidenced. In this figure, it is shown that the
difference in LV MTT is very low among the raters. The
coefficient of variation was lowest for the LV (1.21 %) and
highest for the PTT (3.30 %) (Table 2). Reproducibility for
the measurements between the two time moments
performed by all raters demonstrated an ICC of 0.99
(95 % CI, 0.98–0.99), 0.99 (95 % CI, 0.98–0.99), and 0.94
(95 % CI, 0.92–0.94) for the RV MTT, LV MTT, and PTT,
respectively (Table 3). Reproducibility between the two
time moments for the PTT per rater showed an ICC be-
tween 0.81 and 0.99. The ICC was 0.99 for all technicians;
for the physicians it varied between 0.81 and 0.99 (Table 4).
Bland-Altman analysis revealed a mean difference of 0.10
(±0.54) s between the physicians and technicians. The
95 % limits of agreement ranged from – 0.95 s to 1.16 s
(Fig. 3).
ANOVA analysis of the three repeated injections
showed a mean PTT of 11.4 ± 3.4 s, 11.6 ± 3.4 s, and
11.8 ± 3.2 s at 1:100, 1:200, and 1:400 dilutions of Sono-
Vue® in saline, respectively. The variability amongst the
means was F 0.048, which was not significant (P = 0.95).
The measure of effect for the SonoVue® dose on the PTT
accounted for 2 %, η2 0.02. The means and standard
deviations of the different PTTs per patient per dose are
Table 1 Demographic characteristics
Mean ± SD (n = 15) Min – max (n = 15)
Gender (n male/women) 12/3
Age (yr) 67 ± 7 58–78
Weight (kg) 81 ± 15 51–109
Height (cm) 176 ± 9 158–188
BMI 26 ± 4 19–37
BSA 2.0 ± 0.2 1.5–2.3
NYHA classification n (%)
Class II 7 (47)
Class III 5 (33)
Class IV 3 (20)
Echocardiography
LVEF (%) 31 ± 11 17–53
RV dysfunction
TAPSE < 16 mm (n) 4/15
Pulmonary hypertension
TR velocity > 2.8 m/s (n) 2/15
Electrocardiogram
Heart rate 72 ± 17 50–110
QRS duration (ms) 151 ± 27 118–194
IVMD (ms) in 13 patients 42 ± 14 20–60
SPWMD (ms) in 11 patients 152 ± 70 10–240
Comorbidities n (%)
Hypertension 5 (33)
Coronary artery disease 11 (73)
Congestive heart failure 14 (93)
COPD 6 (40)
Diabetes mellitus 3 (20)
Medication n (%)
Beta-blocker 12 (80)
ACE inhibitors 11 (73)
AT II blockers 2 (13)
Loop diuretics 12 (80)
K-sparing agents 6 (40)
Statins 14 (93)
Laboratory
Creatinine (μmol/L) 105 ± 28 31–160
NT-proBNP (pmol/L) 162 ± 111 36–440
SD standard deviation, BMI body mass index, BSA body surface area, NYHA New
York Heart Association, LVEF left ventricular ejection fraction, RV right ventricle,
TAPSE tricuspid annular plane systolic excursion, TR tricuspid regurgitation, IVMD
interventricular mechanical delay, SPWMD septal to posterior wall motion delay,
COPD chronic obstructive pulmonary disease, ACE angiotensin-converting
enzyme, AT II angiotensine-II-receptor antagonist, K-sparing potassium sparing,
NT-proBNP N-terminal pro-B-type natriuretic peptide
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shown in Fig. 4. The mean PTT and standard deviation
for the three different doses was 11.6 ± 3.3 s. The coeffi-
cient of variation was 5.3 ± 4.4 %. The ROI sizes were
normally distributed and the mean ROI size for the RV
was 12 ± 3 mm2 and for the LV 25 ± 6 mm2. The
coefficient of variation of the ROI size based on the
three different doses was for the RV 11.3 ± 4.5 % and
9.0 ± 5.3 % for the LV.
Discussion
This study demonstrated that measurement of PTT
derived from IDCs of an UCA bolus injected in a per-
ipheral vein is feasible and highly reliable. The inter- and
intra-rater correlations are high, and a very low bias
between physicians and technicians was observed.
Therefore, the drawing of the ROI in the CEUS record-
ings is not only reproducible, but also operator inde-
pendent for measurement of the PTT. According to the
high coefficient of variation of the ROI size, the size
does not influence the PTT measurement. This makes
measurement of the PTT feasible. We also showed that
PTT measurement is repeatable, at three different doses
in the linear range between concentration and acoustic
intensity. The dose did not show any effect on the PTT
measurement. The results are in accordance with the
volumes measured in an in-vitro model [1]. In this previ-
ous study, the volumes were calculated by multiplying
the flow through the circuit by the difference in MTT
between an inflow and outflow tube [1]. A high ICC of
0.99 (95 % CI, 0.98–1.00) was measured for the three
repetitions of an UCA bolus at the same flow and
volume of the circuit.
We previously showed that transthoracic and trans-
esophageal CEUS can be used to estimate transit times
and pulmonary blood volumes in patients [2, 8]. The
values of the PTTs derived with CEUS are in line with
cardiopulmonary transit times measured by low-dose
contrast-enhanced time-resolved magnetic resonance
(MR) angiography, where the magnetic resonance im-
aging (MRI) signal is measured in the pulmonary artery
and ascending aorta [16]. In a patient population similar
to ours, with reduced LV function, Shors et al. (2003)
reported cardiopulmonary transit times of 11.2 ± 4.0 s in
patients with a left ventricular ejection fraction (LVEF)
between 21 and 30 % and 9.0 ± 1.7 s for a LVEF between
31 % and 40 % [16]. Our patient population had a mean
LVEF of 31 % and the average PTT was 11.8 ± 3.0 s.
However, in our cohort two patients had moderate
pulmonary hypertension and four patients had moderate
right ventricle dysfunction (Table 1), both lead to a
prolonged cardiopulmonary circulation times as expressed
by PTT [3]. Although in the study of Shors et al., the ROIs
were drawn at different regions in the heart and vessels,
the transit times are in line with each other. In this study,
three-dimensional gradient-echo fast low-angle shots
imaging was performed through the pulmonary artery and
aorta during inspiration breath-holding [16]. This is
different from our study, where the measurements were
performed without breath-hold. The advantage of ultra-
sound is that the temporal resolution of ultrasound is
much higher (frame rate 23 Hz) than that of MRI
Table 2 Inter-rater reliability of the mean transit times measured
in the right and left ventricle and of the pulmonary transit time of
the two time moments between the eight raters. The coefficient
of variation is expressed as a percentage
ICC (95 % CI) Coefficient of
variation (± SD) %
Right ventricle mean transit time 0.98 (0.97–0.99) 2.61 (3.00)
Left ventricle mean transit time 0.99 (0.98–0.99) 1.21 (1.18)
Pulmonary transit time 0.94 (0.90–0.97) 3.30 (3.35)
ICC intra-class correlation coefficient, CI confidence interval, SD standard deviation
Fig. 2 The fitted curves by eight raters of one patient’s left ventricle indicator dilution curve (IDC) (panel a). The difference in mean transit times
of these fitted IDCs among the eight raters in one patient (panel b)
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(typically 1 Hz, electrocardiographically triggered on the
R-peak depending on the heart rate) [16].
The reliability of our study is in agreement with a
recently-published report on the PTT measured in cats
using CEUS [17]. The time elapsed to pass the pulmonary
circulation by a bolus of SonoVue® was derived by appear-
ance time recording in both the pulmonary artery and left
atrium. Veterinarians with different levels of experience
evaluated the contrast-enhanced short axis echocardiog-
raphy loops. Similarly as in our study, no influence of the
observers’ experience on PTT measurements was found
(median inter-observer variability of 6.8 %) [17]. They
concluded that this procedure is simple and robust, and
does not need to be limited to experienced operators in
echocardiography [17]. Notably, our data suggest the
measurement variability to be even lower by the high ICCs
(Table 2). This can be explained by the way the individual
pulmonary artery or chamber MTTs were estimated. In
this study, PTT was estimated by the appearance of
contrast behind the pulmonic valve and in the left atrium.
Appearance of contrast started or stopped a timer [17]. A
similar way to estimate PTT was used by Choi et al. [4].
In this study, investigating transit time as an estimate for
cardiac output between the RV and LV, the transit time
was 3.2 ± 1.2 s in patients with a mean LVEF of 50 ± 16 %
[4]. The transit time was calculated by identification of the
first bubble appearance, full opacification, and peak
opacification of both ventricles in 27 patients [4]. Incorp-
orating a model like the LDRW, in the MTT assessment,
makes it less subjective to human errors. The model-free
parameters do not take into account the underlying
kinetics of the UCA bolus in the blood stream, like the
Brownian motion described by the LDRW model [12, 18].
Though the transit time estimated by two observers at
two time moments showed a high intra-observer correl-
ation (1 month interval) of 0.92, the inter-observer correl-
ation was lower (0.79) [4]. This can be explained by the
analyses of the UCA passage, by the timing of the first
bubble appearance to full opacification of the ventricles;
this problem could be solved by using LDRW model
fitting, as shown in our results with a higher inter-rater
Table 3 Intra-rater reliability of the mean transit times measured
in the right and left ventricle and of the pulmonary transit time by
all the raters between the two time moments
ICC (95 % CI)
Right ventricle mean transit time 0.99 (0.98–0.99)
Left ventricle mean transit time 0.99 (0.98–0.99)
Pulmonary transit time 0.94 (0.92–0.96)
ICC intra-class correlation coefficient, CI confidence interval
Table 4 Intra-rater reliability per rater for the pulmonary transit
time (PTT). Raters 1,2,3, and 8 are physicians and raters 4,5,6, and 7
are technicians. The mean PTTs of the fifteen patients are
expressed with their standard deviation at time moment 1 and 2,
measured by each rater
ICC (95 % CI) Mean PTT t1 (± SD) Mean PTT t2 (± SD)
Rater 1 0.91 (0.76–0.97) 11.86 (3.14) 12.13 (3.14)
Rater 2 0.99 (0.99–1.00) 11.77 (3.00) 11.69 (2.99)
Rater 3 0.92 (0.79–0.97) 11.82 (3.08) 11.49 (3.22)
Rater 4 0.99 (0.99–1.00) 11.64 (2.89) 11.70 (2.96)
Rater 5 0.99 (0.98–1.00) 11.84 (3.09) 11.82 (2.99)
Rater 6 0.99 (0.99–1.00) 11.76 (3.12) 11.71 (3.03)
Rater 7 0.99 (0.98–1.00) 11.65 (2.95) 11.60 (2.93)
Rater 8 0.81 (0.54–0.93) 12.17 (4.15) 11.60 (2.96)
ICC intra-class correlation coefficient, CI confidence interval, SD standard deviation,
t1 time moment 1, t2 time moment 2
Fig. 3 Bland-Altman analysis. The X-axis represents the mean of the
average pulmonary transit time (PTT) in the two time moments
measured by physicians and technicians. The Y-axis represents the
difference of the average PTTs in the two time moments between
the physicians and technicians. The solid line is the mean difference
(bias); dotted lines are limits of agreement [bias ± (1.96 SD)]
Fig. 4 Means of pulmonary transit times in seconds for each patient
based on three different SonoVue® concentrations, expressed as bullets
and standard deviations as error bars
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reliability. In the feasibility study of the PTT measure-
ment, an ICC of 0.94 was found in nine patients and two
observers using frame counting [3]. This emphasizes the
simplicity of this procedure, which by using a model-
based method may become more accurate.
The total dosage of SonoVue® used to perform the
complete examination according to the protocol was
0.875 mg, which is less than the recommended dose by
Bracco. We did not encounter any side effects of SonoVue®.
Blood pressure, electrocardiogram, and heart rate were
monitored during the examination, and the intravenous
access was left in place for 30 min. The chance of side
effects has been shown to be low; in a large study with
23,188 abdominal CEUS procedures the overall reporting
rate of serious adverse events was 0.0086 % [19]. The
chance of any serious allergic reactions has been shown to
have a very low incidence (estimated to be 1:10 000) [10].
We used for the analyses three injections of SonoVue®
at a total amount of 0.875 mg SonoVue®. Thus, we kept
all our doses in the linear range between concentration
of SonoVue® and acoustic intensity measured by the
ultrasound scanner, avoiding attenuation and shadowing
effects [1, 2]. It has been shown that, provided that no
shadowing occurs, the effect of the ultrasound scanner
settings on the errors in linearization of the video data
exported in DICOM files are kept to a minimum when
the dynamic range is exceeding approximately 45 dB
[20]. Then a wide range of gain values can be used with
excellent agreement with those derived from raw radio-
frequency data [20]. The percent of error on the MTT
measurements, derived from patients with colorectal
liver metastasis, at 50 dB and a gain value of 50 dB was
2.8 ± 3.1 % [21]. At lower dynamic range settings, these
error percentages were higher [21].
Study Limitation
Although promising, some limitations should be consid-
ered in the interpretation of our results. Sensitivity of
the PTT measurement was not addressed in this study.
However, several authors reported over a range of
cardiac function good correlation with the measured
PTT by CEUS. A cut-off point of approximately 4.5 s
distinghuished normals from patients with diminished
function [3, 4]. In our population, with diminished ejec-
tion fractions (± 30 % and dyssynchrony), PTT was
11.2 s. A good differentiation can be appreciated be-
tween the different ventricular functions based on PTT-
measurements, which is also reported in MRI studies as
described above [16, 22].
It is known that intra-cardiac shunts due to for ex-
ample atrial septum defect or ventricular septum defect
will influence the IDC [23]. These shunt characteristics
are well known in transpulmonary thermodilution where
a thermistor is positioned in the femoral artery. In case
of a left-to-right shunt in patients with a ventricular
septum defect the tail of the IDC will show an extra
humb as the indicator will be recycled from the left to
the right atrium [23]. In a right-to-left shunt the IDC
will show a biphasic humb at the ascending part of the
IDC, meaning an earlier increase and decrease of the
curve followed by the actual peak of a normal passage of
the indicator [23, 24]. In our patients no atrial or
ventricular septum defects were present. However, given
the high prevalence of patent foramen ovale (PFO) of
35 % in the general population, we cannot exclude the
presence of a PFO in a part of our patients [25]. Still, a
PFO would probably not influence the results as only a
minority of PFO’s will demonstrate a spontaneous right-
to-left shunt and all patients were spontaneous breathing
without respiratory distress, which means no right-to-
left shunts would be expected. Indeed, most PFO’s only
exhibit shunting during Valsalva manoeuvre. However,
knowing that CEUS is contraindicated in patients with
intra-cardiac shunts and the indicator should only pass
the detection point once, the effect of an intra-cardiac
shunt on the MTT of the left ventricle could be of inter-
est for future studies [10, 26].
Our study population consisted of patients with a
dilated LV and low ejection fraction; this could benefit
the feasibility of ROI drawing in the LV. A larger LV
with diminished contractions could facilitate ROI draw-
ing, reducing interference with the septal and lateral
walls. Indeed a higher coefficient of variation of the
MTT of the much smaller, good contracting RV, 2.61 %
versus 1.21 % for the LV is supported by the higher coef-
ficient of variation of the ROI size of the RV. Neverthe-
less, the ICC of 0.98 for the RV is comparable with the
LV ICC (Table 2). This observation suggests that contri-
bution of ventricular size to the variability of MTT
measurement is limited and implies that MTT measure-
ment in the normal LV is as reliable.
The difference in reliability between the physicians
and non-physicians could not be explained as we did not
include other performance parameters in the present
study, such as time to complete measurements per ROI,
per patient, for the whole set of patients, and the two
time moments. The explanation for this difference needs
to be investigated.
Although, an ICC larger than 0.8 is still almost perfect
according to Landis and Koch (1977), the intra-rater
reliability per rater showed some variation with ICCs
ranging from 0.81 to 0.99 (Table 4) [27]. This variation
can be explained by a deviating MTT measurement at
one of the time moments, which can probably be over-
come by a higher number of repetitions to increase the
precision [28]. In analogy to cardiac output measure-
ments using intermittent bolus thermodilution, three re-
peated injections could be necessary to estimate transit
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times with a high precision. However, for cardiac out-
put estimations, the use of four indicator injections
improved the precision to 5 % compared to the ‘true’
value [28]. The number of repeated injections re-
quired to ensure a high precision for MTT estimation
needs to be explored.
In this study, we did not investigate the effect of
different ultrasonographers on the estimation of the
PTT. However, we showed in an earlier study using
transesophageal echocardiography that the MTT
measurement is easy to perform; a good and stable
view on the chamber or vessel under investigation
during the whole cardiac cycle is necessary [8]. It is
of importance to keep in- and expirations in a normal
and regular pattern, otherwise artifacts may occur due
to the displacement of the heart in the imaging
window.
The development of automated algorithms for ROI
definition and MTT estimation could enhance clinical
feasibility of this novel CEUS tool [29]. This could
create the opportunity to simplify PTT calculation at
the bedside.
The relationship between the PTT and cardiac
function has been investigated mainly by MRI and
radionuclides [16, 30]. The relationship to different
echocardiographic parameters has recently been investi-
gated and seems promising, further investigations are
necessary to evaluate its diagnostic characteristics [3].
Conclusions
PTT assessment by drawing ROIs in CEUS recordings is
a reliable technique with a high inter- and intra-rater re-
liability and reproducibility. Each measurement also
showed a high repeatability between three different echo
loops at three different doses. Differences in ROI size
hardly affect the MTT per ROI. This makes this novel
bedside applicable technique for measuring the PTT re-
liable to be performed by experienced and inexperienced
operators, having an ultrasound scanner and an UCA
with intravenous access. This motivates for further
investigation of its clinical application in order to replace
invasive measurements requiring catheterization.
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